{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:46:23Z","timestamp":1793166383298,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20210146"],"award-info":[{"award-number":["BK20210146"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Project of Jinling Hospital","award":["22LCYY-QH7"],"award-info":[{"award-number":["22LCYY-QH7"]}]},{"name":"Clinical Research Project of Jinling Hospital","award":["22LCYY-LH3"],"award-info":[{"award-number":["22LCYY-LH3"]}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370096"],"award-info":[{"award-number":["82370096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-03958-9","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:15:38Z","timestamp":1740492938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Jing","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangfeng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"3958_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"3958_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553:446\u2013454. https:\/\/doi.org\/10.1038\/nature25183","journal-title":"Nature"},{"key":"3958_CR3","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"3958_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/s0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819\u20131830. https:\/\/doi.org\/10.1016\/s0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"3958_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092645","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, Di Maio M, Tiseo M (2020) Adding PD-1\/PD-L1 inhibitors to chemotherapy for the first-line treatment of extensive stage small cell lung cancer (SCLC): a meta-analysis of randomized trials. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12092645","journal-title":"Cancers (Basel)"},{"key":"3958_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD (2020) Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37:443\u2013455. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.017","journal-title":"Cancer Cell"},{"key":"3958_CR7","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U (2019) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30:1884\u20131901. https:\/\/doi.org\/10.1093\/annonc\/mdz411","journal-title":"Ann Oncol"},{"key":"3958_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","volume":"22","author":"SM Swetter","year":"2024","unstructured":"Swetter SM, Johnson D, Albertini MR et al (2024) NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2024. J Natl Compr Cancer Netw 22:290\u2013298. https:\/\/doi.org\/10.6004\/jnccn.2024.0036","journal-title":"J Natl Compr Cancer Netw"},{"key":"3958_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-018-0362-6","volume":"6","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Atkins MB, Kirkwood JM et al (2018) An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer 6:44. https:\/\/doi.org\/10.1186\/s40425-018-0362-6","journal-title":"J Immunother Cancer"},{"key":"3958_CR10","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/jco.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse DM, Garon EB, Chandler J et al (2020) Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: checkmate 153. J Clin Oncol 38:3863\u20133873. https:\/\/doi.org\/10.1200\/jco.20.00131","journal-title":"J Clin Oncol"},{"key":"3958_CR11","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1111\/1759-7714.15063","volume":"14","author":"Y Feng","year":"2023","unstructured":"Feng Y, Tao Y, Chen H, Zhou Y, Tang L, Liu C, Hu X, Shi Y (2023) Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer 14:2536\u20132547. https:\/\/doi.org\/10.1111\/1759-7714.15063","journal-title":"Thorac Cancer"},{"key":"3958_CR12","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.21037\/jtd.2019.12.23","volume":"11","author":"G Metro","year":"2019","unstructured":"Metro G, Addeo A, Signorelli D et al (2019) Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 \u226550% who progress on first-line immunotherapy: real-world data from a European cohort. J Thorac Dis 11:4972\u20134981. https:\/\/doi.org\/10.21037\/jtd.2019.12.23","journal-title":"J Thorac Dis"},{"key":"3958_CR13","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/1759-7714.15308","volume":"15","author":"K Yamamoto","year":"2024","unstructured":"Yamamoto K, Ninomaru T, Okada H, Hirano K, Shimada T, Hata A (2024) Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer. Thorac Cancer 15:1271\u20131275. https:\/\/doi.org\/10.1111\/1759-7714.15308","journal-title":"Thorac Cancer"},{"key":"3958_CR14","doi-asserted-by":"publisher","first-page":"967559","DOI":"10.3389\/fphar.2022.967559","volume":"13","author":"L Li","year":"2022","unstructured":"Li L, Liu T, Liu Q et al (2022) Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer. Front Pharmacol 13:967559. https:\/\/doi.org\/10.3389\/fphar.2022.967559","journal-title":"Front Pharmacol"},{"key":"3958_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s12094-023-03360-w","volume":"26","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Ye Z, Xie Y et al (2024) Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer. Clin Transl Oncol 26:1357\u20131367. https:\/\/doi.org\/10.1007\/s12094-023-03360-w","journal-title":"Clin Transl Oncol"},{"key":"3958_CR16","doi-asserted-by":"publisher","first-page":"S1072","DOI":"10.1016\/j.annonc.2024.08.1899","volume":"35","author":"C Liu","year":"2024","unstructured":"Liu C, Wu X, Zheng C, Wang Y (2024) 1808P Immunotherapy retreatment with serplulimab versus chemotherapy in extensive-stage advanced small cell lung cancer previously treated with first-line immunotherapy: a real-world retrospective cohort study. Ann Oncol 35:S1072","journal-title":"Ann Oncol"},{"key":"3958_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.37349\/etat.2024.00275","volume":"5","author":"AA Musaelyan","year":"2024","unstructured":"Musaelyan AA, Odintsova SV, Musaelyan KA, Urtenova MA, Solovyova EP, Menshikova LI, Orlov SV (2024) Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer. Explor Target Anti-Tumor Ther 5:1271\u20131288. https:\/\/doi.org\/10.37349\/etat.2024.00275","journal-title":"Explor Target Anti-Tumor Ther"},{"key":"3958_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.967559","author":"L Li","year":"2022","unstructured":"Li L, Liu T, Liu Q et al (2022) Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.967559","journal-title":"Front Pharmacol"},{"key":"3958_CR19","doi-asserted-by":"publisher","first-page":"S854","DOI":"10.1016\/j.annonc.2024.08.1407","volume":"35","author":"M Russano","year":"2024","unstructured":"Russano M, Cantini L, Ap B, George R, Nunes P, Tolba K, Dutra C, Chico I, Cortellini A, Pecci F, Alessi JV (2024) 1352P real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy. Ann Oncol 35:S854","journal-title":"Ann Oncol"},{"key":"3958_CR20","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1016\/j.jtho.2021.01.074","volume":"16","author":"A Spira","year":"2021","unstructured":"Spira A, Monnette A, Wentworth C, Doan J, Chang C, Hartman J (2021) FP02.02 real-world outcomes among advanced non-small cell lung cancer patients re-treated with immunotherapy in the US. J Thorac Oncol 16:S189\u2013S190. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.074","journal-title":"J Thorac Oncol"},{"key":"3958_CR21","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.21037\/jtd-23-1767","volume":"16","author":"X Yan","year":"2024","unstructured":"Yan X, Zhao L, Wu F et al (2024) Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study. J Thorac Dis 16:1787\u20131803. https:\/\/doi.org\/10.21037\/jtd-23-1767","journal-title":"J Thorac Dis"},{"key":"3958_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2114","author":"X Zhao","year":"2024","unstructured":"Zhao X, Cheng Y, Guo C, Nie L, Zhang Q, Zhang M, Sun K, Wang G (2024) Efficacy of cross-line anti-programmed death 1\/programmed cell death-ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: a retrospective study. Health Sci Rep. https:\/\/doi.org\/10.1002\/hsr2.2114","journal-title":"Health Sci Rep"},{"key":"3958_CR23","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.21037\/jtd-22-1611","volume":"15","author":"M Xu","year":"2023","unstructured":"Xu M, Hao Y, Zeng X, Si J, Song Z (2023) Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer. J Thorac Dis 15:1648\u20131657. https:\/\/doi.org\/10.21037\/jtd-22-1611","journal-title":"J Thorac Dis"},{"key":"3958_CR24","doi-asserted-by":"publisher","first-page":"1266992","DOI":"10.3389\/fimmu.2023.1266992","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Xiong X, Cheng Y, Gen H, Zhu W, Zhang F, Zhu C, Han S, Liu X (2023) Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression. Front Immunol 14:1266992. https:\/\/doi.org\/10.3389\/fimmu.2023.1266992","journal-title":"Front Immunol"},{"key":"3958_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.21037\/tlcr-20-1252","volume":"9","author":"X Ge","year":"2020","unstructured":"Ge X, Zhang Z, Zhang S et al (2020) Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 9:2391\u20132400. https:\/\/doi.org\/10.21037\/tlcr-20-1252","journal-title":"Transl Lung Cancer Res"},{"key":"3958_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1186\/s12885-024-12315-5","volume":"24","author":"M Wang","year":"2024","unstructured":"Wang M, Jing X, Chen F, Lu S, Sun Y (2024) Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer. BMC Cancer 24:569. https:\/\/doi.org\/10.1186\/s12885-024-12315-5","journal-title":"BMC Cancer"},{"key":"3958_CR27","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.jtho.2018.08.2027","volume":"13","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, von Pawel J, Mazieres J et al (2018) Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol 13:1906\u20131918. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2027","journal-title":"J Thorac Oncol"},{"key":"3958_CR28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"3958_CR29","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","volume":"124","author":"S Tan","year":"2020","unstructured":"Tan S, Li D, Zhu X (2020) Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother 124:109821. https:\/\/doi.org\/10.1016\/j.biopha.2020.109821","journal-title":"Biomed Pharmacother"},{"key":"3958_CR30","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 30:1321\u20131328. https:\/\/doi.org\/10.1093\/annonc\/mdz167","journal-title":"Ann Oncol"},{"key":"3958_CR31","doi-asserted-by":"publisher","first-page":"e000498","DOI":"10.1136\/esmoopen-2019-000498","volume":"4","author":"AS Berghoff","year":"2019","unstructured":"Berghoff AS, Bellosillo B, Caux C et al (2019) Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open 4:e000498. https:\/\/doi.org\/10.1136\/esmoopen-2019-000498","journal-title":"ESMO Open"},{"key":"3958_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","volume":"15","author":"F Guisier","year":"2020","unstructured":"Guisier F, Dubos-Arvis C, Vi\u00f1as F et al (2020) Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01\u20132018. J Thorac Oncol 15:628\u2013636. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.129","journal-title":"J Thorac Oncol"},{"key":"3958_CR33","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.21037\/tlcr-22-376","volume":"11","author":"T Tian","year":"2022","unstructured":"Tian T, Yu M, Yu Y et al (2022) Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study. Transl Lung Cancer Res 11:1027\u20131037. https:\/\/doi.org\/10.21037\/tlcr-22-376","journal-title":"Transl Lung Cancer Res"},{"key":"3958_CR34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2023.12.015","volume":"19","author":"P Bischoff","year":"2024","unstructured":"Bischoff P, Reck M, Overbeck T et al (2024) Outcome of first-line treatment with pembrolizumab according to KRAS\/TP53 mutational status for nonsquamous programmed death-ligand 1\u2013high (\u2265 50%) NSCLC in the German national network genomic medicine lung cancer. J Thorac Oncol 19:803\u2013817","journal-title":"J Thorac Oncol"},{"key":"3958_CR35","doi-asserted-by":"publisher","first-page":"e432524","DOI":"10.1200\/EDBK_432524","volume":"44","author":"N Frost","year":"2024","unstructured":"Frost N, Reck M (2024) Non-small cell lung cancer metastatic without oncogenic alterations. Am Soc Clin Oncol Educ Book 44:e432524","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3958_CR36","doi-asserted-by":"publisher","first-page":"e2300953","DOI":"10.1002\/advs.202300953","volume":"10","author":"C Cheng","year":"2023","unstructured":"Cheng C, Wang P, Yang Y, Du X, Xia H, Liu J, Lu L, Wu H, Liu Q (2023) Smoking-induced M2-TAMs, via circEML4 in EVs, promote the progression of NSCLC through ALKBH5-regulated m6A modification of SOCS2 in NSCLC Cells. Adv Sci (Weinh) 10:e2300953. https:\/\/doi.org\/10.1002\/advs.202300953","journal-title":"Adv Sci (Weinh)"},{"key":"3958_CR37","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s12276-022-00784-2","volume":"54","author":"SB Kwak","year":"2022","unstructured":"Kwak SB, Kim SJ, Kim J, Kang YL, Ko CW, Kim I, Park JW (2022) Tumor regionalization after surgery: roles of the tumor microenvironment and neutrophil extracellular traps. Exp Mol Med 54:720\u2013729. https:\/\/doi.org\/10.1038\/s12276-022-00784-2","journal-title":"Exp Mol Med"},{"key":"3958_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002990","author":"MJ Wagner","year":"2021","unstructured":"Wagner MJ, Othus M, Patel SP et al (2021) Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002990","journal-title":"J Immunother Cancer"},{"key":"3958_CR39","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"3958_CR40","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/s0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929\u20131939. https:\/\/doi.org\/10.1016\/s0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"3958_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, Farago AF, de Braud F et al (2019) Third-line nivolumab monotherapy in recurrent SCLC: CHECKMATE 032. J Thorac Oncol 14:237\u2013244. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.003","journal-title":"J Thorac Oncol"},{"key":"3958_CR42","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L et al (2022) Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA 328:1223\u20131232. https:\/\/doi.org\/10.1001\/jama.2022.16464","journal-title":"JAMA"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03958-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03958-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03958-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T09:20:04Z","timestamp":1743067204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03958-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3958"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03958-9","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Research involving human participants and their data was approved by Ethics Committee of Jinling Hospital, and individual consent for this retrospective analysis was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"124"}}